Impact of Latent Tuberculosis Infection on Neurocognitive Functioning and Inflammation in HIV-Infected and Uninfected South Indians.
Adult
Anti-HIV Agents
/ therapeutic use
Antiretroviral Therapy, Highly Active
Chemokine CCL2
/ blood
Cognition
/ physiology
Cognitive Dysfunction
/ pathology
Cross-Sectional Studies
Female
HIV Infections
/ drug therapy
Humans
India
Interferon-gamma
/ blood
Interleukin-6
/ blood
Latent Tuberculosis
/ pathology
Male
Young Adult
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 08 2020
01 08 2020
Historique:
pubmed:
14
4
2020
medline:
17
2
2021
entrez:
14
4
2020
Statut:
ppublish
Résumé
HIV-associated neurocognitive disorder persists in some people living with HIV despite optimal antiretroviral therapy. Latent tuberculosis infection (LTBI) may cause systemic inflammation and immune activation that may impair brain function. We assessed cognition and biomarkers of inflammation in both HIV+ and HIV- South Indians with and without LTBI. Adults (≥18 years old) with and without HIV infection were screened for LTBI by interferon-gamma release assays, completed comprehensive neurocognitive assessments, and underwent measurement of serum inflammatory biomarker levels. The participants (n = 119) were HIV+/LTBI+ (n = 15), HIV+/LTBI- (n = 50), HIV-/LTBI+ (n = 26), and HIV-/LTBI- (n = 28). HIV+ participants, regardless of LTBI status, had more impaired global deficit scores than HIV- participants (odds ratio = 3.42, P = 0.028, adjusted for sex and education differences). Neither global deficit scores nor impairment rates differed in the LTBI+ group compared with the LTBI- group (P = 0.79 and P = 0.41, respectively). The mean log10 interleukin (IL)-6 and monocyte chemoattractant protein-1 values were significantly higher and high sensitivity C-reactive protein lower in the LTBI+ group than the LTBI- group (P = 0.044, 0.023, and 0.03, respectively, adjusting for HIV status and sex). In this cross-sectional study of South Indians, HIV infection, but not LTBI, was associated with increased neurocognitive impairment. Proinflammatory biomarkers (IL-6 and monocyte chemoattractant protein-1, but not tumor necrosis factor-α) were elevated in the LTBI+ groups compared with the LTBI- groups. Biomarkers of immune activation (interferon-γ, macrophage inflammatory protein-1β, IL-2, interferon gamma inducible protein-10, RANTES, and IL-22) did not differ between these groups. Larger longitudinal studies should be conducted to confirm our findings that the effect of LTBI on systemic inflammation or neurocognitive impairment is likely small.
Sections du résumé
BACKGROUND
HIV-associated neurocognitive disorder persists in some people living with HIV despite optimal antiretroviral therapy. Latent tuberculosis infection (LTBI) may cause systemic inflammation and immune activation that may impair brain function. We assessed cognition and biomarkers of inflammation in both HIV+ and HIV- South Indians with and without LTBI.
METHODS
Adults (≥18 years old) with and without HIV infection were screened for LTBI by interferon-gamma release assays, completed comprehensive neurocognitive assessments, and underwent measurement of serum inflammatory biomarker levels.
RESULTS
The participants (n = 119) were HIV+/LTBI+ (n = 15), HIV+/LTBI- (n = 50), HIV-/LTBI+ (n = 26), and HIV-/LTBI- (n = 28). HIV+ participants, regardless of LTBI status, had more impaired global deficit scores than HIV- participants (odds ratio = 3.42, P = 0.028, adjusted for sex and education differences). Neither global deficit scores nor impairment rates differed in the LTBI+ group compared with the LTBI- group (P = 0.79 and P = 0.41, respectively). The mean log10 interleukin (IL)-6 and monocyte chemoattractant protein-1 values were significantly higher and high sensitivity C-reactive protein lower in the LTBI+ group than the LTBI- group (P = 0.044, 0.023, and 0.03, respectively, adjusting for HIV status and sex).
CONCLUSIONS
In this cross-sectional study of South Indians, HIV infection, but not LTBI, was associated with increased neurocognitive impairment. Proinflammatory biomarkers (IL-6 and monocyte chemoattractant protein-1, but not tumor necrosis factor-α) were elevated in the LTBI+ groups compared with the LTBI- groups. Biomarkers of immune activation (interferon-γ, macrophage inflammatory protein-1β, IL-2, interferon gamma inducible protein-10, RANTES, and IL-22) did not differ between these groups. Larger longitudinal studies should be conducted to confirm our findings that the effect of LTBI on systemic inflammation or neurocognitive impairment is likely small.
Identifiants
pubmed: 32282443
doi: 10.1097/QAI.0000000000002368
pmc: PMC7321856
mid: NIHMS1582949
pii: 00126334-202008010-00014
doi:
Substances chimiques
Anti-HIV Agents
0
CCL2 protein, human
0
Chemokine CCL2
0
IFNG protein, human
0
IL6 protein, human
0
Interleukin-6
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
430-436Subventions
Organisme : NIMH NIH HHS
ID : K23 MH085512
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062512
Pays : United States
Références
EBioMedicine. 2015 Apr 1;2(4):334-340
pubmed: 26114158
Clin Infect Dis. 2019 May 2;68(10):1739-1746
pubmed: 30137250
Clin Neuropsychol. 2004 May;18(2):234-48
pubmed: 15587671
Am J Trop Med Hyg. 2019 Jun;100(6):1512-1520
pubmed: 31017077
J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):281-8
pubmed: 25469522
AIDS. 2010 Jun 1;24(9):1243-50
pubmed: 19996937
Curr HIV Res. 2004 Jul;2(3):275-82
pubmed: 15279591
PLoS One. 2014 Nov 04;9(11):e110104
pubmed: 25369472
PLoS One. 2018 Sep 13;13(9):e0202191
pubmed: 30212453
J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):190-7
pubmed: 24442225
Clin Infect Dis. 2018 Aug 16;67(5):770-777
pubmed: 29506084
J Gerontol A Biol Sci Med Sci. 2015 Jul;70(7):873-8
pubmed: 25161214
J Clin Exp Neuropsychol. 2004 May;26(3):307-19
pubmed: 15512922
Microbiol Mol Biol Rev. 2014 Sep;78(3):343-71
pubmed: 25184558
Neurology. 2012 Feb 14;78(7):485-92
pubmed: 22330412
J Clin Exp Neuropsychol. 2011 Aug;33(7):793-804
pubmed: 21547817
Annu Rev Immunol. 2013;31:475-527
pubmed: 23516984
J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):31-6
pubmed: 15608521
Neurology. 2003 Jul 8;61(1):76-80
pubmed: 12847160
Pathog Immun. 2016 Fall-Winter;1(2):291-303
pubmed: 27853753
J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):110-117
pubmed: 30531294
Clin Infect Dis. 2016 Dec 15;63(12):1655-1660
pubmed: 27794019
Am J Med. 2004 Apr 5;116 Suppl 7A:27S-43S
pubmed: 15050884
HIV AIDS (Auckl). 2019 May 30;11:133-139
pubmed: 31213927
Neurology. 2010 Dec 7;75(23):2087-96
pubmed: 21135382
Clin Infect Dis. 2018 Mar 5;66(6):886-892
pubmed: 29069328
Scand J Immunol. 2011 Mar;73(3):234-42
pubmed: 21204895
J Neurovirol. 2019 Dec;25(6):792-799
pubmed: 31281947
J Infect Dis. 2016 Apr 1;213(7):1065-73
pubmed: 26690344